Trade Adaptive Biotechnologies Corporation - ADPT CFD

Adaptive Biotechnologies Corporation Company profile

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Adaptive Biotechnologies Corp revenues increased 57% to $154.3M. Net loss increased 42% to $207.3M. Revenues reflect Sequencing revenue segment increase of 90% to $78.9M, Development revenue segment increase of 32% to $75.4M. Higher net loss reflects Research and development - Balancing increase of 19% to $128.3M (expense), General and administrative - Balancing increase of 47% to $59.7M (expense).